文献速递临床试验与 GCP

WHO MBMDT与含利福平、莫西沙星和克拉霉素月度化疗方案(RMC)治疗多菌型麻风患者的多中心非劣效性临床试验方案

Protocol of a comparative multicentric non inferiority clinical trial of WHO MBMDT with a new monthly chemotherapy regimen containing rifampicin, moxifloxacin and clarithromycin (RMC) on multibacillary patients from India.
PubMed 文献 · Trials · 2026-02-17

该方案描述了一项在印度四家麻风病 Mission 医院开展的多中心随机临床试验,纳入初治多菌型麻风患者,随机接受12个月WHO MBMDT或月度RMC方案,主要用分子活力试验评估疗效并密切监测不良事件。

要点

  • 多菌型麻风初治患者随机接受12个月WHO MBMDT或月度RMC方案。
  • 主要疗效指标采用分子活力试验评估,并密切监测不良事件。
  • 试验在印度四家三级医院开展,遵循CONSORT指南。

核心结论

  • 该试验旨在比较月度RMC方案与WHO MBMDT治疗多菌型麻风的疗效,以探索更优方案。

研究设计与样本

  • 多中心随机临床试验,在印度德里、北方邦、西孟加拉邦和恰蒂斯加尔邦的麻风病 Mission 信托三级医院开展,遵循CONSORT指南。
  • 初治多菌型麻风患者随机分配接受12个月WHO MBMDT或月度RMC方案。

关键数值与推荐

  • 主要目标是评估月度RMC方案相比WHO MBMDT治疗多菌型麻风的疗效。
  • 疗效评估采用分子活力试验,并密切监测不良事件。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Current WHO MBMDT regimen has largely been successful in treating leprosy patients since 1984, when it was implemented worldwide. According to clinical presentation, pauci and multibacillary leprosy, the regimen is also given for 6 or 12 months. However, this regimen has its limitations, such as incomplete bacterial clearance, prolonged treatment duration and poor patient compliance, necessitating administration of alternative and more effective regimens. Secondly, there is a subset of patients who are highly bacillated and continue to harbour viable bacilli even after treatment and thus continue transmission. We present the protocol of WHOMDT vs. monthly regimen of rifampicin, moxifloxacin and clarithromycin (RMC), a randomised clinical trial designed to test the efficacy of the RMC regimen in the management of multibacillary leprosy. METHODS AND ANALYSIS: MB MDT vs RMC clinical trial is multicentric which will be conducted in accordance with the CONSORT guidelines in The Leprosy Mission Trust India's tertiary care hospitals at Delhi, Uttar Pradesh, West Bengal and Chhattisgarh. Naive MB leprosy patients who consent to participate will be randomly allocated to receive 12 months of WHO MB MDT or a monthly regimen of rifampicin, moxifloxacin and clarithromycin. The primary objective will be to evaluate the efficacy of monthly RMC regimen compared to the WHOMBMDT in treating multibacillary leprosy. Molecular viability assay will be used to assess the efficacy of the regimen. Monitoring of adverse events will be closely done. ETHICS AND DISSEMINATION: Results will be submitted for publication in peer-reviewed journals. Ethical approval has been obtained from The Leprosy Mission Trust India's ethics committee (TLMTI/EC/C-69). This study is registered at Clinical Trials Registry-India (CTRI) - CTRI/2024/03/064435.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Darlong J, Nessa S, Singh I, et al. Protocol of a comparative multicentric non inferiority clinical trial of WHO MBMDT with a new monthly chemotherapy regimen containing rifampicin, moxifloxacin and clarithromycin (RMC) on multibacillary patients from India. Trials. 2026. PMID: 41699691. doi:10.1186/s13063-026-09544-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。